At the movement Castlight Health, Inc. (NYSE:CSLT) is under coverage by number of analysts. Buy rating has been given by 1 analysts to the company stock and 7 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Hold and their mean rating for the stock is 2.67 on scale of 1-5. Analysts mean target price for Castlight Health, Inc. (NYSE:CSLT) is $4.71 while their mean recommendation is 2.60 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved up 22.22% to end the day at $3.85. The current share price indicate that stock is -30.00% away from its one year high and is moving 44.19% ahead of its 52-week low.
Castlight Health, Inc. (NYSE:CSLT) reported a loss of $9.1 million in its fourth quarter. On a per-share basis, the San Francisco-based company said it had a loss of 9 cents. Losses, adjusted for stock option expense and costs related to mergers and acquisitions, came to 1 cent per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 4 cents per share. The online health care software company posted revenue of $29.9 million in the period, which also topped Street forecasts. Three analysts surveyed by Zacks expected $28.4 million. For the year, the company reported that its loss narrowed to $58.5 million, or 58 cents per share. Revenue was reported as $101.7 million.
On 16 February 2017, Cantel Medical Corp. (NYSE:CMD) shares moved to $82.48 after starting the day at $81.18. Number of analysts are covering this stock and currently 2 analysts given HOLD rating to the stock.
Cantel Medical Corp. (NYSE:CMD) announced that it entered into a definitive agreement to purchase its endoscopy business assets from Australian distributor, CR Kennedy & Company Pty Ltd. The endoscopy business assets consist of Cantel’s Medivators®-branded automated endoscope reprocessors, chemistries, procedure room products and other consumables as well as a full sales and service organization. Jorgen B. Hansen, President and CEO of Cantel Medical said, “This acquisition is in line with Cantel’s strategy to expand its products and services into key markets to provide global solutions that meet local needs. It also accelerates our ability to offer customers in Australia an expanded Medivators®-branded product portfolio while maintaining the high-quality service and support that our customers expect.” “The expansion of our commercial platform and the addition of a direct sales and service organization for our Endoscopy business provides Cantel with near- and long-term growth opportunities. It also broadens our leadership and strengthens our share in the infection prevention market in Australia,” stated David Rosen, President, Continental Europe, Middle East and Asia-Pacific. “We would like to thank CR Kennedy for the many years of outstanding support of the Medivators® business in Australia and for their partnership and role in helping us achieve this milestone.”